explore -WSS

explore

author：leisure time 2025-09-28 21:05:22 - browse：61669

Have you ever seen a mouse with a set of muscles more appropriate for a bodybuilder or comic book superhero?

Well, 25 years ago, researchers at Johns Hopkins University made it happen. By silencing a gene responsible for producing a protein called myostatin, they directed tiny mouse bodies to grow double the amount of lean muscle they would normally, leading to mice with bulky arms, defined pectorals, and an overall more substantial body mass. They were dubbed “mighty mice.”

Now, biotech startups are hoping to use those findings to create what they believe will be better weight loss medications. In the last several months, multiple companies have disclosed they are testing drugs that preserve or grow muscle while reducing fat, as shown in the updated STAT Obesity Drug Tracker. They hope that their drugs, possibly when used in conjunction with existing obesity treatments, will result in healthier weight loss.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： The biotech scorecard for Q1: 17 stock

WSS

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

3 trends to watch in health tech's hiring outlook for 2024

Feng Zhang CRISPR delivery startup lays off quarter of staff

Chronically ill young patients struggle to find fertility info

Burning questions for the 2024 JPM Healthcare Conference

AdventHealth escalates lawsuit against insurance vendor Multiplan

entertainment

explore

leisure time

Bright Health sells Medicare Advantage business to Molina

Federal weight loss drug coverage is 30 years out of date

Trump demands the U.S. pay no more for drugs than other countries … again

New weight loss drugs work. But how can they best be used?

Guidelines to prevent youth baseball injuries need more muscle

White House finalizes ITC's import ban of latest Apple Watches

Dobbs anniversary: the lost opportunity of abortion as health care

AdventHealth escalates lawsuit against insurance vendor Multiplan

Dobbs anniversary: the lost opportunity of abortion as health care

Federal weight loss drug coverage is 30 years out of date

focus

3 trends to watch in health tech's hiring outlook for 2024

A single drug, study failures leave Anavex with nothing but cash

Videos point to link between seizures and unexplained toddler deaths

U.K. sequencing study surfaces new findings about tumor DNA

Ahead of JPM, here's who's profiting most in health care

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

focus

explore

focus

Wikipedia